Data updated: Mar 29, 2026

BIOMARIN PHARM

Pharmaceuticals

Specialty

BIOMARIN PHARM is a specialty pharmaceutical company with 7 FDA-approved products.

2003

Since

7

Drugs

-

Trials

9

Approved (2yr)

Key Drugs

elosulfase alfa

Mannose-6-phosphate receptor 2 indications · 2014

cerliponase alfa

M6P/IGF2 receptor 1 indications · 2017

NPR-B 1 indications · 2021

Top Drug Revenues ProEarly access

Loading...

Revenue Over Time ProEarly access

Loading...

Competitive Matchups ProEarly access

Loading...

Recent Activity

PALYNZIQ 2025-11-20

VIMIZIM 2025-10-30

VOXZOGO 2024-11-04

NAGLAZYME 2024-09-12

KUVAN 2024-08-26

KUVAN 2024-08-26

BRINEURA 2024-07-24

NAGLAZYME 2024-07-10

SEC Filings ProEarly access

Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

No indication data

Pipeline Forecast

Loading...

Upcoming Trial Milestones ProEarly access

Loading...

Patent Cliff ProEarly access

Loading...